|
|
Background
|
![]() |
|
Constance Benson, M.D. is a Professor of Medicine, Senior Attending Physician, and the Infectious Disease Fellowship Training Program Director in the Department of Medicine/Division of Infectious Diseases at the University of California, San Diego School of Medicine. She is also the Principal Investigator and Chair of the Executive Committee and Vice Chair of the Scientific Steering Committee of the NIH/NIAID AIDS Clinical Trials Group (ACTG), Principal Investigator of the NIH/NIAID UCSD AIDS Clinical Trials Unit, and is a past chair of the NIH Office of AIDS Research Advisory Council.
Dr. Benson is an internationally-recognized researcher and clinician in the field of HIV and AIDS. Her areas of research focus include Mycobacterium avium complex disease, other HIV-related opportunistic infections, metabolic complications of HIV therapies, antiretroviral treatment and new antiretroviral drug development, treatment of acute HIV-1 infection, and the treatment of HIV infection and its complications in resource-limited international settings. Her contributions to the field of HIV/AIDS are numerous. To date, she has published more than 220 original manuscripts, book chapters and abstracts reporting and summarizing findings from HIV-related research. She has served on numerous NIH ad hoc study sections and scientific review groups, has served as a reviewer for 11 major medical journals, and lectures frequently both nationally and internationally on topics within her areas of research and clinical expertise.
Dr. Benson is a member of the International AIDS Society, the Infectious Disease Society of America, the HIV Medicine Association of the IDSA, the American Association for the Advancement of Science, and the American College of Physicians. She participates on numerous academic and extramural committees and is a member of the Board of Directors of the International AIDS Society-USA and the Foundation for Human Retrovirology. She also serves on the Scientific Program Committee of the Conference on Retroviruses and Opportunistic Infections (CROI), and participates in reviewing papers submitted to the International AIDS Society-sponsored World AIDS Conferences.
Dr. Benson received her B.S. and M.D. degrees from The Ohio State University in Columbus, OH. She completed her internship and residency in Internal Medicine and her fellowship in Infectious Diseases at Rush University Medical Center in Chicago, IL. She served in the U.S. Navy Medical Corps at the Great Lakes Naval Regional Medical Center prior to continuing her career in academic infectious diseases. She was a faculty member of Rush Medical College and the School of Medicine at the University of Colorado Health Sciences Center before assuming her current position as Professor of Medicine in the University of California, San Diego School of Medicine. She maintains clinical duties as a specialist in infectious diseases and as an active provider of HIV/AIDS care at the University of California, San Diego Medical Center in San Diego.
|
|
|
|
|
Faculty Page
|
![]() |
|
Constance Benson, M.D.Professor of Medicine
Program Director, Fellowship
AVRC
150 W. Washington St.
Mail Code 8208
San Diego. California 92103
Phone: 619-543-8080
Fax: 619-298-0177
Email: cbenson@ucsd.edu
Dr. Benson’s major research interests are in the treatment of HIV-1 related opportunistic infections (in particular Mycobacterium avium complex and tuberculosis), the pathogenesis and treatment of acute HIV-1 infection, complications of HIV therapies, evaluation of antiretroviral treatment strategies and new antiretroviral drug development, and capacity building and research training for HIV/AIDS in resource-limited international settings. In addition to her role as protocol chair on completed ACTG studies, Dr. Benson is the protocol chair of current ACTG studies A5001 and A5086, as well as a protocol team member/co-investigator of A5029 and A5217.
|
|
|
|
|
Selected Publications
|
![]() |
|
Currier JS, Williams PL, Becker S, Feinberg J, Owens S, Fichtenbaum C, Benson C. Impact of prophylaxis for Mycobacterium avium complex (MAC) on bacterial infections in advanced HIV disease. Clin Infect Dis 2001; 32:1615-22.
2. Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Andersen J, Squires K, Benson C. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS Clinical Trials Group studies. J Infect Dis 2001; 184:1325-1327.
3. Benson CA, Deeks S, Brun SC, Gulick R, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and two nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor experienced patients. J Infect Dis 2002; 185:599-607.
4. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquired Immunodeficiency Syndrome 2002; 31:257-275.
5. Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, et al. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003; 73:159-69.
6. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, Notario GF, Hafner R. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:1234-43.
7. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RB. MDR1 gene polymorphisms and phase I viral decay during HIV-1 infection. J Acquir Immune Defic Syndr 2003; 34:295-8.
8. Hicks C, King MS, Gulick RM, White AC, Jr., Eron JJ, Jr., Kessler HA, Benson C, King KR, Murphy RL, Brun SC. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. AIDS 2004; 18:775-9.
9. Benson CA, van der Horst C, LaMarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004; 18(17):2269-76.
10. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR 2004; 53(RR-15):1-112 (also Clin Infect Dis 2005)
|
|
|